Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
To compare safety of adjuvant OFS combined with anastrozole versus OFS combined with
exemestane in Chinese premenopausal hormonal receptor(HR) positive breast cancer patients.